Multiple Sacituzumab Tirumotecan (sac-TMT) Studies Selected as LBAs at ESMO 2026, OptiTROP-Lung04 and OptiTROP-Lung06 to be Presented in the Lung Cancer Session

ConferenceSacituzumab TirumotecanPositive

AI Analysis

Summary

Multiple Phase III studies of sacituzumab tirumotecan (sac-TMT/SKB264/MK-2870) have been selected as Late-Breaking Abstracts for presentation at the 2026 ESMO Congress in Madrid, with OptiTROP-Lung04 and OptiTROP-Lung06 to be presented in the lung cancer session.

Clinical Trial Data

Phase

Phase 3

Outcome Details

Multiple Phase III studies selected as Late-Breaking Abstracts (LBAs) for presentation at ESMO 2026

Importance:6/10

Sentiment:

0.60

TROP2 ADClung cancerESMO 2026late-breaking abstractsOptiTROP-Lung04OptiTROP-Lung06

Related Companies

$MRK

Read the original article

Published by PR Newswire Biotech on September 22, 2026 7:40 AM

Read Original